Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%? - Arcus Biosciences (NYSE:RCUS)

HC Wainwright lifted Arcus Biosciences' price target, citing broader revenue potential for casdatifan in first-line ccRCC.

Raccontata dabenzinga.com